Literature DB >> 24441287

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.

O Landgren1, B I Graubard2, J A Katzmann3, R A Kyle4, I Ahmadizadeh1, R Clark3, S K Kumar4, A Dispenzieri4, A J Greenberg5, T M Therneau4, L J Melton5, N Caporaso2, N Korde1, M Roschewski1, R Costello1, G M McQuillan6, S V Rajkumar4.   

Abstract

Multiple myeloma (MM) incidence is markedly higher in blacks compared with whites, which may be related to a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS). Our objective was to define the prevalence and risk factors of MGUS in a large cohort representative of the US population. Stored serum samples from the National Health and Nutritional Examination Survey (NHANES) III or NHANES 1999-2004 were available for 12,482 individuals of age ⩾50 years (2331 'blacks', 2475 Hispanics, 7051 'whites' and 625 'others') on which agarose-gel electrophoresis, serum protein immunofixation, serum-free light-chain assay and M-protein typing were performed. MGUS was identified in 365 participants (2.4%). Adjusted prevalence of MGUS was significantly higher (P<0.001) in blacks (3.7%) compared with whites (2.3%) (P=0.001) or Hispanics (1.8%), as were characteristics that posed a greater risk of progression to MM. The adjusted prevalence of MGUS was 3.1% and 2.1% for the North/Midwest versus South/West regions of the United States, respectively (P=0.052). MGUS is significantly more common in blacks, and more often has features associated with higher risk of progression to MM. A strong geographic disparity in the prevalence of MGUS between the North/Midwest versus the South/West regions of the United States was found, which has etiologic implications.

Entities:  

Mesh:

Year:  2014        PMID: 24441287      PMCID: PMC4090286          DOI: 10.1038/leu.2014.34

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  28 in total

1.  Socioeconomic status and multiple myeloma among US blacks and whites.

Authors:  D Baris; L M Brown; D T Silverman; R Hayes; R N Hoover; G M Swanson; M Dosemeci; A G Schwartz; J M Liff; J B Schoenberg; L M Pottern; J Lubin; R S Greenberg; J F Fraumeni
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

2.  Sample design: Third National Health and Nutrition Examination Survey.

Authors:  T M Ezzati; J T Massey; J Waksberg; A Chu; K R Maurer
Journal:  Vital Health Stat 2       Date:  1992-09

3.  The National Health and Nutrition Examination Survey: Sample Design, 1999-2006.

Authors:  Lester R Curtin; Leyla K Mohadjer; Sylvia M Dohrmann; Jill M Montaquila; Deanna Kruszan-Moran; Lisa B Mirel; Margaret D Carroll; Rosemarie Hirsch; Susan Schober; Clifford L Johnson
Journal:  Vital Health Stat 2       Date:  2012-05

4.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

5.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

Review 6.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

Review 7.  Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis.

Authors:  O Landgren; B M Weiss
Journal:  Leukemia       Date:  2009-07-09       Impact factor: 11.528

Review 8.  Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

Authors:  A J Greenberg; C M Vachon; S V Rajkumar
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

9.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

10.  Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Julie A Britton; Aneire E Khan; Sabine Rohrmann; Nikolaus Becker; Jakob Linseisen; Alexandra Nieters; Rudolf Kaaks; Anne Tjønneland; Jytte Halkjaer; Marianne Tang Severinsen; Kim Overvad; Tobias Pischon; Heiner Boeing; Antonia Trichopoulou; Victoria Kalapothaki; Dimitrios Trichopoulos; Amalia Mattiello; Giovanna Tagliabue; Carlotta Sacerdote; Petra H M Peeters; H Bas Bueno-de-Mesquita; Eva Ardanaz; Carmen Navarro; Paula Jakszyn; Jone M Altzibar; Göran Hallmans; Beatrice Malmer; Göran Berglund; Jonas Manjer; Naomi Allen; Timothy Key; Sheila Bingham; Hervé Besson; Pietro Ferrari; Mazda Jenab; Paolo Boffetta; Paolo Vineis; Elio Riboli
Journal:  Haematologica       Date:  2008-10-02       Impact factor: 9.941

View more
  50 in total

1.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors: 
Journal:  Am J Hematol       Date:  2018-08-16       Impact factor: 10.047

Review 2.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  Racial disparities, cancer and response to oxidative stress.

Authors:  Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew
Journal:  Adv Cancer Res       Date:  2019-04-23       Impact factor: 6.242

Review 4.  Second malignancies in multiple myeloma; emerging patterns and future directions.

Authors:  Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

Review 5.  Multiple myeloma epidemiology and survival: A unique malignancy.

Authors:  Dickran Kazandjian
Journal:  Semin Oncol       Date:  2016-11-10       Impact factor: 4.929

Review 6.  Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Authors:  Sikander Ailawadhi; Kirtipal Bhatia; Sonikpreet Aulakh; Zahara Meghji; Asher Chanan-Khan
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

7.  The screening imperative for multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Nature       Date:  2020-11       Impact factor: 49.962

Review 8.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

Review 9.  Racial and ethnic disparities in hematologic malignancies.

Authors:  Kedar Kirtane; Stephanie J Lee
Journal:  Blood       Date:  2017-07-19       Impact factor: 22.113

10.  Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance.

Authors:  Weixin Wang; Youn K Shim; Joel E Michalek; Emily Barber; Layla M Saleh; Byeong Yeob Choi; Chen-Pin Wang; Norma Ketchum; Rene Costello; Gerald E Marti; Robert F Vogt; Ola Landgren; Katherine R Calvo
Journal:  J Toxicol Environ Health A       Date:  2020-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.